HOME | CONTACT | BLOG | SITE MAP   

Press Releases

Leading Regenerative Veterinary Medicine Company, VetStem Biopharma, announces the addition of Dr. Mark Hughes as the Senior Manager, Veterinary Clinical Research and Safety.

VetStem Biopharma proudly announces Dr. Mark Hughes as the Senior Manager, Veterinary Clinical Research and Safety.

June 13, 2016 --

VetStem Biopharma proudly announces Dr. Mark Hughes as the Senior Manager, Veterinary Clinical Research and Safety. Dr. Hughes, former Product Development Manager in R&D at Virbac Corporation, brings eight years of experience managing drug development projects through the process of pharmaceutical development, preclinical and clinical trials, and submissions to regulatory authorities for marketing approval in the US and Canada. Dr. Hughes received BS, MS, and DVM degrees from the University of California, Davis, and is licensed to practice in California. He also has provided commercial embryo transfer services for beef and dairy cattle, developed in-vitro diagnostics for diseases in animals and people, and managed a laboratory animal research facility.

 

“With 8 years of experience in the veterinary product development market and having extensive experience in clinical field trials Dr. Hughes will be a great addition to our team.”  Dr. Robert Harman, CEO, explains. “Dr. Hughes will be responsible for the continued development of new services, products and clinical data generation.  We believe with his previous history and understanding of the product development process, he will efficiently guide our projects through the FDA approval process.”

 

“I am very pleased to join the VetStem Biopharma team to be an integral part of a dynamic, industry-leading company in a field with breakthrough potential for treating a diverse range of diseases and injuries in companion animals and horses,” said Dr. Hughes. “I am excited to participate in the development of products that truly will benefit our animal friends worldwide.”

 

VetStem is currently in the product development phase for the first off-the-shelf stem cell product for the canine osteoarthritis. As many as two thirds of dogs over 7 years old are affected by osteoarthritis,  which has created the largest existing market segment in pet therapeutics.  Although currently marketed products can help decrease the crippling symptoms of osteoarthritis, they are not designed to regenerate and heal the damaged tissue that is causing pain.  Regenerative medicine focuses on true regeneration of damaged tissues and organs. 

 

 





< Back to Press Releases     

 


  • Success Stories
    News
    Videos
    Blog
    Press Releases
    Facebook
    Twitter
     


      COMPANY
    Management
    Investors
    Contact Us
    Careers
    SCIENCE
    FAQs
    Literature Refs
    Safety
    PET & HORSE OWNERS
    Dogs & Cats
    Horses
    Locate a Vet
    FAQs
    VETERINARIANS
    Vet Login /
    Credentialing

    Dogs & Cats
    Horses
    FAQs
    MEDIA ROOM
    Press Releases
    Success Stories
    News
    Videos
    Blog
    LOCATE A VET

    CONTACT US
     

    COPYRIGHT 2011 VETSTEM BIOPHARMA. ALL RIGHTS RESERVED.
    12860 Danielson Court, Suite B, Poway, CA 92064 Phone: 858-748-2004 or 888-387-8361